Dosing  de novo  combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

Sariah Liu; Mina Nikanjam; Razelle Kurzrock

doi:10.18632/oncotarget.7023

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

Sariah Liu _, Mina Nikanjam and Razelle Kurzrock

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:11310-11320. https://doi.org/10.18632/oncotarget.7023

Metrics: PDF 1128 views | HTML 2612 views | ?

Abstract

Sariah Liu1,*, Mina Nikanjam2,*, Razelle Kurzrock3

1Department of Hematology-Oncology, Kaiser Permanente San Diego Medical Center, San Diego, CA, USA

2Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA

3Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, San Diego, CA, USA

*These authors have contributed equally to this work

Correspondence to:

Mina Nikanjam, e-mail: [email protected]

Keywords: oncology, targeted therapy, maximum tolerated dose, recommended phase 2 dose, precision medicine

Received: October 05, 2015 Accepted: January 15, 2016 Published: January 25, 2016

ABSTRACT

Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted drug combinations, we identified clinical trials in adult oncology patients who received targeted drug doublets (PubMed, January 1, 2010 through December 31, 2013). The dose percentage was calculated for each drug: (safe dose in combination divided by single agent full dose) X 100. Additive dose percentage represented the sum of the dose percentage for each drug. A total of 144 studies (N = 8568 patients; 95 combinations) were analyzed. In 51% of trials, each of the two drugs could be administered at 100% of their full dose. The lowest safe additive dose percentage was 60% if targets and/or class of drugs overlapped, or in the presence of mTor inhibitors, which sometimes compromised the combination dose. If neither class nor target overlapped and if mTor inhibitors were absent, the lowest safe additive dose percentage was 143%. The current observations contribute to the knowledge base that informs safe starting doses for new combinations of targeted drugs in the context of clinical trials or practice, hence facilitating customized combination therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7023

Publication Alerts

Research Papers:

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

Abstract